SELLAS Life Sciences (SLS) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 14, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	SELLAS Life Sciences Group, Inc.
Entity Central Index Key	0001390478
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Emerging Growth	false
Entity Shell Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		4,871,927

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 9,119	$ 5,337
Restricted cash and cash equivalents	115	114
Prepaid expenses and other current assets	977	387
Total current assets	10,211	5,838
Operating lease right-of-use asset	306
In-process research and development	8,500	8,500
Goodwill	1,914	1,914
Deposits and other assets	553	663
Total assets	21,484	16,915
Current liabilities:
Accounts payable	3,764	3,755
Accrued expenses and other current liabilities	1,504	2,219
Operating lease liability, current	306
Total current liabilities	5,574	5,974
Operating lease liability, non-current	0
Deferred tax liability	357	357
Warrant liability	80	1,013
Contingent consideration	4,836	4,326
Total liabilities	10,847	11,670
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2019 and December 31, 2018	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized, 4,549,208 and 440,529 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively.	5	1
Additional paid-in capital	104,360	87,099
Accumulated deficit	(93,728)	(81,855)
Total stockholders’ equity	10,637	5,245
Total liabilities and stockholders’ equity	$ 21,484	$ 16,915

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	4,549,208	440,529
Common stock, shares outstanding (in shares)	4,549,208	440,529
Series A Preferred Stock
Preferred stock, shares authorized (in shares)	17,500	17,500

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
Research and development	$ 1,799	$ 1,720	$ 5,039	$ 5,116
General and administrative	2,385	1,341	7,523	10,130
Total operating expenses and operating loss	(4,184)	(3,061)	(12,562)	(15,246)
Non-operating income (expense):
Change in fair value of warrant liability	(49)	2,241	1,108	5,340
Change in fair value of contingent consideration	(28)	(162)	(510)	(4,025)
Loss on settlement of liability-classified warrants	0	0	0	(727)
Gain on extinguishment of debt	0	766	0	766
Interest income (expense), net	59	(74)	91	(292)
Total non-operating income (expense), net	(18)	2,771	689	1,062
Loss before income taxes	(4,202)	(290)	(11,873)	(14,184)
Income tax expense	0	0	0	163
Net loss	(4,202)	(290)	(11,873)	(14,347)
Deemed dividend arising from beneficial conversion feature of convertible preferred stock	0	0	0	(4,436)
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	0	(8,654)	0	(8,654)
Deemed dividend arising from warrant modifications	(7,268)	(491)	(8,659)	(491)
Net loss attributable to common stockholders	$ (11,470)	$ (9,435)	$ (20,532)	$ (27,928)
Per share information:
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)	$ (2.68)	$ (26.75)	$ (11.37)	$ (137.43)
Weighted-average common shares outstanding, basic and diluted (in shares)	4,281,855	352,713	1,805,773	203,223

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Series A Preferred Stock	Preferred Stock	Preferred StockSeries A Preferred Stock	Common Stock	Common StockSeries A Preferred Stock	Additional Paid-In Capital	Additional Paid-In CapitalSeries A Preferred Stock	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2017			0		115,337
Beginning balance at Dec. 31, 2017	$ 2,070		$ 0		$ 1		$ 56,254		$ (54,185)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and common stock warrants, net of issuance costs (in shares)					136,900
Issuance of common stock and common stock warrants, net of issuance costs	21,564						21,564
Issuance of stock (in shares)			10,700
Issuance of stock		$ 9,647						$ 9,647
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering	(5,039)						(5,039)
Beneficial conversion feature arising from Series A convertible preferred stock	(4,436)						(4,436)
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock	4,436						4,436
Issuance of common stock as repayment of principal and interest on long-term debt (in shares)			(2,898)	(7,802)	9,993	74,963
Issuance of common stock to Series A convertible preferred stockholders under most favored nation provision		$ (8,654)						$ (8,654)
Issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	8,654						8,654
Convertible preferred stock dividends	(487)						(487)
Issuance of common stock as repayment of principal and interest on long-term debt (in shares)					14,305
Issuance of common stock as repayment of principal and interest on long-term debt	2,896						2,896
Issuance of common stock in connection with litigation settlements (in shares)					4,573
Issuance of common stock in connection with litigation settlements	1,250						1,250
Issuance of common stock upon conversion of promissory notes (in shares)					2,372
Issuance of common stock upon conversion of promissory notes	825						825
Issuance of common stock in connection with warrant exchange agreements (in shares)					1,086
Issuance of common stock in connection with warrant exchange agreements	285						285
Issuance of common stock upon exercise of warrants (shares)					50,495
Impact of anti-dilution protection on liability-classified warrants	(491)						(491)
Stock-based compensation	284						284
Net loss	(14,347)								(14,347)
Ending balance (in shares) at Sep. 30, 2018			0		410,024
Ending balance at Sep. 30, 2018	18,457		$ 0		$ 1		86,988		(68,532)
Beginning balance (in shares) at Jun. 30, 2018			7,802		147,670
Beginning balance at Jun. 30, 2018	(2,483)		$ 0		$ 1		65,758		(68,242)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and common stock warrants, net of issuance costs (in shares)					136,900
Issuance of common stock and common stock warrants, net of issuance costs	21,564						21,564
Issuance of common stock upon exercise of pre-funded warrants (shares)					50,491
Issuance of common stock as repayment of principal and interest on long-term debt (in shares)			(7,802)		74,963
Issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	(8,654)						(8,654)
Issuance of common stock to Series A convertible preferred stockholders under most favored nation provision	8,654						8,654
Convertible preferred stock dividends	(470)						(470)
Stock-based compensation	136						136
Net loss	(290)								(290)
Ending balance (in shares) at Sep. 30, 2018			0		410,024
Ending balance at Sep. 30, 2018	18,457		$ 0		$ 1		86,988		(68,532)
Beginning balance (in shares) at Dec. 31, 2018			0		440,529
Beginning balance at Dec. 31, 2018	5,245		$ 0		$ 1		87,099		(81,855)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and common stock warrants, net of issuance costs (in shares)					527,344
Issuance of common stock and common stock warrants, net of issuance costs	13,416						13,416
Issuance of stock (in shares)					2,095,949
Issuance of stock	3,658				$ 2		3,656
Issuance of common stock upon exercise of pre-funded warrants (shares)					1,485,156
Issuance of common stock upon exercise of pre-funded warrants	8				$ 2		6
Impact of anti-dilution protection on liability-classified warrants	(243)						(243)
Issuance of common stock upon vesting of restricted stock units (shares)					230
Issuance of common stock upon vesting of restricted stock units.	0
Stock-based compensation	426						426
Net loss	(11,873)								(11,873)
Ending balance (in shares) at Sep. 30, 2019			0		4,549,208
Ending balance at Sep. 30, 2019	10,637		$ 0		$ 5		104,360		(93,728)
Beginning balance (in shares) at Jun. 30, 2019			0		2,002,702
Beginning balance at Jun. 30, 2019	14,338		$ 0		$ 2		103,862		(89,526)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock (in shares)					2,032,950
Issuance of stock	383				$ 2		381
Issuance of common stock upon exercise of pre-funded warrants (shares)					513,326
Issuance of common stock upon exercise of pre-funded warrants	3				$ 1		2
Issuance of common stock upon vesting of restricted stock units (shares)					230
Issuance of common stock upon vesting of restricted stock units.	0
Stock-based compensation	115						115
Net loss	(4,202)								(4,202)
Ending balance (in shares) at Sep. 30, 2019			0		4,549,208
Ending balance at Sep. 30, 2019	$ 10,637		$ 0		$ 5		$ 104,360		$ (93,728)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (11,873)	$ (14,347)
Adjustment to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt	0	(766)
Non-cash interest expense	0	134
Deferred taxes	0	49
Non-cash stock-based compensation	426	284
Fair value of common stock issued in connection with litigation settlements	0	1,250
Change in fair value of common stock warrants	(1,108)	(5,340)
Change in fair value of contingent consideration	510	4,025
Loss on settlement of liability-classified warrants	0	727
Changes in operating assets and liabilities:
Other receivable	0	(6,600)
Prepaid expenses and other assets	(480)	(538)
Litigation settlement insurance recovery	0	(474)
Accounts payable	(227)	(4,453)
Accrued expenses and other current liabilities	(715)	182
Net cash used in operating activities	(13,467)	(25,867)
Cash flows from financing activities:
Net proceeds from issuance of Series A convertible preferred stock and common stock warrants	0	9,647
Proceeds from issuance of common stock, net of offering costs	13,652	21,564
Net proceeds from exercise of warrants	3,598	0
Dividends paid	0	(487)
Principal payments on long-term debt	0	(7,525)
Net cash provided by financing activities	17,250	23,199
Net increase (decrease) in cash, cash equivalents, restricted cash, and restricted cash equivalents	3,783	(2,668)
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	5,451	12,750
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	9,234	10,082
Supplemental disclosure of cash flow information:
Cash received during the periods for interest	87	166
Cash paid during the periods for interest	0	321
Supplemental disclosure of non-cash investing and financing activities:
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost	0	5,039
Repayment of interest and principal on long-term debt through issuance of common stock	0	3,587
Reclassification of warrant liabilities upon exchange for shares of common stock	0	285
Operating right of use asset and current and non-current liability	550
Impact of anti-dilution protection on liability-classified warrants	243	491
Offering expenses in accounts payable and accrued expenses and other current liabilities	236	0
Long-term debt issued in connection with warrant exchange agreements	0	966
Reclassification of warrant liabilities upon exercise	$ 68	$ 0

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Overview SELLAS Life Sciences Group, Inc. (the "Company" or “SELLAS”) is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications. As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS") in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.

Liquidity

Liquidity	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Liquidity The Company has not generated any revenues, including from product sales, and has funded operations primarily from the proceeds of sales of its equity interests and convertible notes. Additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company’s research and development efforts will be successful. On June 18, 2019, the Company consummated an underwritten public offering (the “June 2019 Offering”) of (i) 527,344 shares of common stock, (ii) 1,472,656 pre-funded warrants exercisable for shares of common stock, and (iii) accompanying common stock warrants to purchase up to an aggregate of 2,000,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $7.50 per share and accompanying common stock warrant. Each common stock warrant sold with the shares of common stock represented the right to purchase one share of common stock at an exercise price of $25.00 per share and, commencing July 10, 2019, could be exercised pursuant to the terms thereof on a cashless basis, at the option of the holder, in whole or in part, for one share of common stock, if the weighted average price of the common stock on any trading day immediately prior to the exercise date is lower than the then-applicable exercise price per share. As of September 30, 2019, 1,997,740 of the June 2019 Offering warrants were cashlessly exercised and 2,260 warrants remain outstanding. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of $7.495 per pre-funded warrant and common stock warrant. The pre-funded warrants were exercisable immediately, at an exercise price of $0.005 per share. As of September 30, 2019, all of the pre-funded warrants sold in the June 2019 Offering were exercised. The net proceeds to the Company from the June 2019 Offering, after deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, was approximately $13.4 million . See Notes 7 and 8 for further discussion of the June 2019 Offering. On March 6, 2019, the Company entered into a Warrant Exercise Agreement (the "Exercise Agreement") with one of the holders of the Company's warrants issued in July 2018. Pursuant to the Exercise Agreement, the warrant holder agreed to exercise for cash up to 76,000 of its warrants issued in July 2018 ("2018 Warrants") into shares of common stock at an adjusted exercise price of $55.00 per share for any 2018 Warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the 2018 Warrants, the Exercise Agreement also provided for the issuance of new warrants to purchase up to an aggregate of approximately 76,000 shares of common stock at an exercise price of $70.00 per share ("New Warrants") to be issued on a share-for-share basis in an amount equal to the number of the 2018 Warrants that were cash exercised by the warrant holder prior to May 31, 2019. During the nine months ended September 30, 2019, the warrant holder exercised approximately 63,000 2018 Warrants for gross proceeds of $3.5 million and approximately 63,000 New Warrants were issued. The Exercise Agreement expired on May 31, 2019. The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. On October 29, 2019, the Company entered into an Equity Distribution Agreement (the "Distribution Agreement") with Maxim Group LLC (the "Agent"). From time to time during the term of the Distribution Agreement, the Company may offer and sell shares of common stock having an aggregate offering price up to a total of $5.0 million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Distribution Agreement will be offered and sold pursuant to the Company's effective registration statement on Form S-3. Subsequent to September 30, 2019, the Company sold 322,719 shares of common stock pursuant to the Distribution Agreement for net proceeds of $1.9 million . Other than the Distribution Agreement, the Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently, or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. As of September 30, 2019 , the Company had cash and cash equivalents of approximately $9.1 million , and restricted cash and cash equivalents of $0.1 million . The Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit of $93.7 million as of September 30, 2019 . In addition, the Company had aggregate outstanding accounts payable and accrued expenses and other current liabilities of $5.6 million as of September 30, 2019 . The Company expects its cash as of September 30, 2019 , together with the net proceeds received from the sale of common stock pursuant to the Distribution Agreement subsequent to September 30, 2019 , will enable the Company to fund its operating expenses and capital expenditure requirements through the third quarter of 2020. The Company has evaluated the guidance of Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern , in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year from the date its financial statements are available to be issued. The Company has prepared its condensed consolidated financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company's ability to continue as a going concern. Various internal and external factors will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or the risk of failure of any such product candidates at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

Basis Of Presentation and Signi

Basis Of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies The Summary of Significant Accounting Policies included in the Company's 2018 Annual Report have not materially changed, except as set forth below. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Reverse Stock Split On November 6, 2019, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1 - for - 50 reverse stock split of the Company's outstanding shares of common stock which became effective on November 7, 2019. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance, under the Company’s equity incentive plans and employee stock purchase plan, were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans were proportionately adjusted for the reverse stock split. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at November 8, 2019 from 227,800,147 to 4,549,208 , after the cancellation of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a cash payment in lieu of such fractional shares. These condensed consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly. Principles of Consolidation The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, Sellas Life Sciences Group UK Ltd., and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar. Unaudited Interim Results These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2018 Annual Report. The accompanying condensed consolidated financial statements at September 30, 2019 and for the three and nine months ended September 30, 2019 and 2018, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2018 have been derived from the audited financial statements as of that date. Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands): September 30, 2019 December 31, 2018 Cash and cash equivalents $ 9,119 $ 5,337 Restricted cash and cash equivalents 115 114 Total cash, cash equivalents, restricted cash, and restricted cash equivalents $ 9,234 $ 5,451 The Company maintained restricted cash and cash equivalents as of September 30, 2019 and December 31, 2018 as collateral for its corporate credit cards. Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity. Recent Accounting Pronouncements Adopted In July 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-07, Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update). ASU No. 2019-07 clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. ASU No. 2019-07 became effective upon issuance and the adoption of ASU No. 2019-07, which is applied prospectively, did not have an impact on the Company’s consolidated financial statements and disclosures. On January 1, 2019, the Company adopted ASU No. 2016-02, Leases ( Topic 842 ), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use ("ROU") assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. The new guidance retains a distinction between finance leases and operating leases, while requiring companies to recognize both types of leases on their balance sheet. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the criteria for distinguishing between capital leases and operating leases in legacy U.S. GAAP - ASC 840. The Company adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company evaluated the potential cumulative effect of applying the new guidance and determined that such an adjustment would be immaterial. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the Company's historical accounting under Topic 840. Under Topic 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on the Company's understanding of what the Company's credit rating would be. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise such options. In connection with the adoption, the Company did not separate lease and associated non-lease components for the transitioned leases, but instead are accounting for them together as a single component. The adoption did not change the classification of lease-related expenses in the condensed consolidated statements of operations, and the Company does not expect changes to the pattern of expense recognition. As a result, the adoption does not impact the Company's beginning retained earnings, or the Company's prior year condensed consolidated statements of operations and will not materially affect the condensed consolidated statements of cash flows. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity Topic (480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instrument with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception , which modifies the classification of some financial instruments. A down round feature no longer precludes equity classification, therefore a freestanding equity feature would no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities present earnings per share in accordance with Topic 260, and to recognize the effect of the down round feature when triggered. Convertible instruments are now subject to specialized contingent beneficial conversion features. The Company adopted ASU No. 2017-11 on January 1, 2019 and determined it did not have a material impact to its condensed consolidated financial statements. The Company determined its liability classified warrants contained cash settlement features that would continue to preclude equity classification subsequent to its adoption of ASU No. 2017-11. Recent Accounting Pronouncements Pending Adoption In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Accounting , which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements. In August 2018, FASB issued No. ASU 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement . ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820 . The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and to delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands): Description September 30, 2019 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 9,055 $ 9,055 $ — $ — Total assets measured and recorded at fair value $ 9,055 $ 9,055 $ — $ — Liabilities: Warrant liability $ 80 $ — $ — $ 80 Contingent consideration 4,836 — — 4,836 Total liabilities measured and recorded at fair value $ 4,916 $ — $ — $ 4,916 Description December 31, 2018 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 5,195 $ 5,195 $ — $ — Total assets measured and recorded at fair value $ 5,195 $ 5,195 $ — $ — Liabilities: Warrant liability $ 1,013 $ — $ — $ 1,013 Contingent consideration 4,326 — — 4,326 Total liabilities measured and recorded at fair value $ 5,339 $ — $ — $ 5,339 The Company did not transfer any financial instruments into or out of Level 3 classification during the nine months ended September 30, 2019 or the year ended December 31, 2018 . See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the nine months ended September 30, 2019 . A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September 30, 2019 is as follows (in thousands): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Contingent consideration, December 31, 2018 $ 4,326 Change in the estimated fair value of the contingent consideration 510 Contingent consideration, September 30, 2019 $ 4,836 The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena’s acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to the Company’s nelipepimut-S ("NPS") product candidate. The contingent consideration is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration unless it has first obtained approval of its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows.

Balance Sheet Accounts

Balance Sheet Accounts	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts Prepaid expenses and other current liabilities consist of the following (in thousands): September 30, 2019 December 31, 2018 Insurance $ 479 $ 154 Clinical development 347 48 Professional services 107 56 Other 44 129 Prepaid expenses and other current assets $ 977 $ 387 Accrued expenses and other current liabilities consist of the following (in thousands): September 30, 2019 December 31, 2018 Compensation and related benefits $ 735 $ 675 Clinical trial costs 441 858 Professional fees 328 540 Rebates and returns of former commercial products — 138 Other — 8 Accrued expenses and other current liabilities $ 1,504 $ 2,219

Legal Proceedings, Commitments

Legal Proceedings, Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings, Commitments and Contingencies	Legal Proceedings, Commitments and Contingencies Office Space Rental The Company has a non-cancelable operating lease for office space in New York, New York, which began August 1, 2018 with a term through July 31, 2020. As disclosed in Note 3, the Company adopted ASC 842 in the first quarter of 2019 and as a result of the adoption, the Company recognized a current operating lease liability of $0.4 million and a non-current operating lease liability of $0.2 million with a corresponding ROU asset of $0.6 million , which is based on the present value of the minimum rental payments of the lease. The discount rate used to account for the Company's operating lease under ASC 842 is the Company’s estimated incremental borrowing rate of 13% . As of September 30, 2019 , the lease has a remaining term of less than 1.0 year. Rent expense related to the Company's operating lease was approximately $0.1 million for the three months ended September 30, 2019 and 2018. Rent expense for the nine months ended September 30, 2019 and 2018 was approximately $0.3 million . Future minimum rental payments under the Company's non-cancelable operating lease are as follows as of September 30, 2019 (in thousands): September 30, 2019 Year ending December 31, 2019 (remaining three months) $ 96 Year ending December 31, 2020 224 Total minimum lease payments 320 Less: imputed interest (14 ) Operating lease liabilities $ 306 Operating lease amortization of the ROU asset was $0.1 million and $0.2 million for the three and nine months ended September 30, 2019 , respectively. Future minimum rental payments under the Company's non-cancelable operating lease as of December 31, 2018 were as follows (in thousands): December 31, 2018 2019 $ 377 2020 224 Total minimum lease payments $ 601 Legal Proceedings From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its condensed consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company’s consolidated results of operations, financial position or cash flows. The Company’s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal, and to which the Company is now subject, as follows: On February 13, 2017, multiple putative shareholder securities class action complaints were filed in federal court alleging, among other things, that the Company and certain of the Company's former officers and directors failed to disclose that Galena’s promotional practices for Abstral® (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena’s statements about its business misleading. The individual actions were consolidated, lead plaintiffs were named by the federal court and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss. Plaintiffs have 30 days from November 13, 2019 to file an amended complain. In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company’s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company’s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company’s former directors, officers and employees, and the Company as a nominal defendant. In June 2018, a derivative complaint was filed in U.S. District Court for the Northern District of California against the Company’s current and former directors, and the Company as a nominal defendant. The plaintiff in the June 2018 case voluntarily withdrew his complaint from the U.S. District Court of the Northern District of California and on August 27, 2018 refiled the complaint in the Court of Chancery of the State of Delaware. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company’s behalf against the Company’s former directors and, in certain of the complaints, the Company’s current directors, and the Company’s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The March 2017, July 2017, and January 2018 lawsuits are currently stayed pending resolution of motions to dismiss in the referenced securities class action. The defendants in the August 2018 lawsuit filed a motion to dismiss the complaint. On November 13, 2019, the August 2018 lawsuit was dismissed without prejudice by the Court of Chancery of the State of Delaware.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. Common Stock The Company has authorized up to 350,000,000 shares of common stock, $0.0001 par value per share, for issuance. On October 29, 2019, the Company entered into the Distribution Agreement with the Agent, pursuant to which the Company may offer and sell shares of common stock through the Agent having an aggregate offering price up to $5.0 million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Sales of the shares, if any, under the Distribution Agreement may be made in transactions that are deemed to be "at the market offering" as defined in Rule 415 under the Securities Act. The Company has no obligation to sell any shares under the Distribution Agreement, and may use the Distribution Agreement until it is terminated by either the Agent or the Company, as permitted thereby. Shares sold, if any, under the Distribution Agreement will be offered and sold pursuant to the Company's effective registration statement on Form S-3. Subsequent to September 30, 2019, the Company sold 322,719 shares of common stock pursuant to the Distribution Agreement for net proceeds of $1.9 million . On June 18, 2019, the Company consummated the June 2019 Offering of (i) 527,344 shares of common stock, (ii) 1,472,656 pre-funded warrants exercisable for shares of common stock, and (iii) accompanying common stock warrants to purchase up to an aggregate of 2,000,000 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $7.50 per share and common stock warrant. The pre-funded warrants and accompanying common stock warrants were sold at a combined price of $7.495 per pre-funded warrant and common stock warrant. Each pre-funded warrant represents the right to purchase one share of the Company’s common stock at an exercise price of $0.005 per share. The net proceeds to the Company from the June 2019 Offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants, were approximately $13.4 million . As of September 30, 2019, the Company has shares of common stock reserved for future issuance for as follows (in thousands): September 30, 2019 Warrants outstanding 302 Stock options outstanding 23 Options reserved for future issuance under the Company’s 2019 Equity Incentive Plan 201 Shares reserved for future issuance under the Employee Stock Purchase Plan 5 Total common stock reserved for future issuance 531

Warrants to Acquire Shares of C

Warrants to Acquire Shares of Common Stock	9 Months Ended
	Sep. 30, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrants to Acquire Shares of Common Stock	Warrants to Acquire Shares of Common Stock Warrants Issued in 2018 On July 16, 2018, the Company issued the 2018 Warrants to purchase up to an aggregate of 230,400 shares of common stock, with an exercise price per share of $105.00 . The 2018 Warrants were immediately exercisable and expire on July 16, 2023. On March 6, 2019, the Company entered into the Exercise Agreement with one of the holders of the 2018 Warrants. Pursuant to the Exercise Agreement, such warrant holder agreed to exercise for cash up to 76,000 of the 2018 Warrants for shares of common stock at an adjusted exercise price of $55.00 per share for any 2018 Warrants exercised prior to May 31, 2019. In addition to reducing the exercise price of the 2018 Warrants held by the warrant holder, the Exercise Agreement also provided for the issuance of the New Warrants to purchase up to an aggregate of approximately 76,000 shares of common stock at an exercise price of $70.00 per share to be issued on a share-for-share basis in an amount equal to the number of the 2018 Warrants that were cash exercised by the warrant holder prior to May 31, 2019. The New Warrants expire five years from the date of issuance. During the nine months ended September 30, 2019, the warrant holder exercised approximately 63,000 of the 2018 Warrants for gross proceeds to the Company of $3.5 million and approximately 63,000 New Warrants were issued. The reduced exercise price of the 63,000 2018 Warrants exercised by the warrant holder increased the fair value of these Existing Warrants by approximately $0.3 million during the nine months ended September 30, 2019, which is recorded as a deemed dividend increasing the net loss attributable to common stockholders and in additional paid-in capital. The Exercise Agreement expired on May 31, 2019. Pursuant to the terms of certain warrants issued in connection with our previously outstanding Series A Convertible Preferred stock in March 2018 and May 2018, the exercise price of these warrants was automatically adjusted on March 6, 2019 to $55.00 per share from the previous exercise price of $105.00 per share as a result of the Company's entry into the Exercise Agreement. The Company recognized the $0.3 million increase to the fair value of the warrant liability as a result of the adjusted exercise price as a deemed dividend which increased the net loss attributable to common stockholders during the nine months ended September 30, 2019. Additionally, the Company agreed to seek the approval of The Nasdaq Stock Market, by November 8, 2019, to reduce the exercise price to $7.50 per share (subject to adjustment for stock splits and the like) of the New Warrants. Prior to November 8, 2019, the Company requested such approval from The Nasdaq Stock Market. In connection with the June 2019 Offering, the Company reduced the exercise price of the 2018 Warrants to $7.50 per share from the previous exercise price of $105.00 per share. The reduced exercise price of the 2018 Warrants increased the value of fair value of the 2018 Warrants by approximately $0.8 million and is recorded as a deemed dividend increasing net loss attributable to common stockholders and additional paid-in-capital during the nine months ended September 30, 2019. Pursuant to the terms of certain liability-classified warrants issued in connection with our previously outstanding Series A Convertible Preferred stock in March 2018 and May 2018, the exercise price of these warrants was automatically adjusted on June 18, 2019 to $7.50 per share from the previous exercise price of $55.00 per share. The Company recognized the $0.1 million increase to the fair value of the warrant liability as a result of the adjusted exercise price as a deemed dividend which increased the net loss attributable to common stockholders during the nine months ended September 30, 2019. July 2019 Investor Agreements On July 8, 2019, the Company entered into a series of Investor Agreements (collectively, the "Investor Agreements") with certain purchasers of securities (each an "Investor") in connection with the June 2019 Offering. In connection with the Investor Agreements, the parties thereto agreed to, among other things, (i) amend the expiration date of those certain leak-out agreements previously entered into with certain Investors in connection with the June 2019 Offering from August 2, 2019 to August 15, 2019, (ii) amend the warrants issued to such Investors in connection with the June 2019 Offering such that they became cashlessly exercisable pursuant to the terms thereof on July 10, 2019 (the "Warrant Amendment"), and (iii) amend the warrant agreement entered into with Computershare Trust Company, N.A. on June 18, 2019 to reflect the terms of the Warrant Amendment. The reduced exercise price from $25.00 to $0.00 resulted in the Company recognizing a $7.3 million deemed dividend, during the three and nine months ended September 30, 2019, increasing net less loss attributable to common stockholders and additional paid-in capital. Warrants Outstanding The following is a summary of the Company's warrants to acquire shares of common stock activity for the nine months ended September 30, 2019 (in thousands): Warrant Issuance Outstanding, December 31, 2018 Granted Exercised Canceled/Expired Outstanding, September 30, 2019 Expiration June 2019 Offering — 2,000 (1,998 ) — 2 June 2024 Pre-funded June 2019 Offering — 1,473 (1,473 ) — — June 2024 March 2019 Exercise Agreement — 63 — — 63 March 2024 July 2018 Offering 305 — (97 ) — 208 July 2023 Pre-funded July 2018 Offering 13 — (13 ) — — July 2023 Series A Convertible Preferred 28 — (9 ) — 19 September 2023 2017 Equilibria 6 — — — 6 December 2022 Galena February 2017 1 — — — 1 February 2022 Galena Other 3 — — — 3 January 2022 356 3,536 (3,590 ) — 302 Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants. Warrants Classified as Liabilities Liability-classified warrants consist of warrants to acquire common stock issued in connection with previous equity financings for the Series A Convertible Preferred stock, Galena's February 2017 financing, and various other Galena equity financings that were assumed by the Company at the consummation of the Merger. These warrants may be settled in cash and were determined to not be indexed to the Company’s common stock. The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: As of September 30, 2019 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Series A Convertible Preferred 19 $ 7.50 4.01 105.47 % 1.56 % Galena February 2017 1 $ 1,650.00 2.38 107.21 % 1.56 % Galena Other 3 $ 41,494.00 1.68 107.21 % 1.56 % As of December 31, 2018 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Series A Convertible Preferred 28 $ 7.50 4.76 88.80 % 2.50 % Galena February 2017 1 $ 1,650.00 3.12 94.12 % 2.46 % Galena Other 3 $ 41,494.00 2.43 94.73 % 2.46 % The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero , because the Company has no present intention to pay cash dividends. The changes in fair value of the warrant liability for the nine months ended September 30, 2019 were as follows (in thousands): Warrant Issuance Warrant liability, December 31, 2018 Fair value of warrants granted Fair value of warrants exercised Adjustment to exercise price of warrants Change in fair value of warrants Warrant liability, September 30, 2019 Series A Convertible Preferred $ 1,010 $ — $ (68 ) $ 243 $ (1,108 ) $ 77 Galena February 2017 3 — — — — 3 $ 1,013 $ — $ (68 ) $ 243 $ (1,108 ) $ 80 Warrants Classified as Equity The Company issued warrants to acquire 6,323 shares of the its common stock at an exercise price of $371.00 per share, maturing five years from issuance, to EQC Private Markets SAC Fund Ltd-EQC Biotech Sely I Fund on December 29, 2017. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued during the June 2019 Offering and July 2018 Offering were recorded in equity upon issuance. During its evaluation of equity classification for the pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock issued in the June 2019 Offering, the Company considered the conditions as prescribed within ASC 815-40, Derivatives and Hedging, Contracts in an Entity’s own Equity (“ASC 815-40”). The conditions within ASC 815-40 are not subject to a probability assessment. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, Distinguishing Liabilities from Equity , as they are not puttable and do not represent an instrument that has a redeemable underlying security. The pre-funded warrants exercisable for shares of common stock and warrants to acquire shares of common stock do meet the definition of a derivative instrument under ASC 815, but are eligible for the scope exception as they are indexed to the Company’s own stock and would be classified in permanent equity if freestanding. In addition, the Company determined that the down round feature in the warrants to acquires shares of common stock issued in the June 2019 Offering did not preclude equity classification. As described in Note 3, on January 1, 2019, the Company adopted ASU No. 2017-11, which changed the classification of certain equity-linked financial instruments (or embedded features) with down round features. A down round feature no longer precludes equity classification, therefore a freestanding equity feature would no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation 2017 Equity Incentive Plan On December 29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, and currently allows for the issuance of up to a maximum of 24,204 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. 2019 Equity Incentive Plan On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, and currently allows for issuance of up to (i) 200,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) any shares of common stock that are represented by awards granted under the Company’s 2017 Equity Incentive Plan that are forfeited, expire or are cancelled without delivery of shares of common stock or which result in the forfeiture of shares of common stock back to the Company on or after September 10, 2019. As of September 30, 2019, an aggregate of 1,018 shares of common stock under the 2017 Equity Incentive Plan were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1 of each year, for a period of not more than four years, commencing on January 1, 2020 and ending on (and including) January 1, 2023, by an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of September 30, 2019 , 201,018 shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 and 2018 , respectively (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development $ (1 ) $ 21 $ (4 ) $ 55 General and administrative 116 115 430 229 Total stock-based compensation $ 115 $ 136 $ 426 $ 284 Options to Purchase Shares of Common Stock The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2019 and 2018: Nine Months Ended September 30, 2019 2018 Risk free interest rate 2.49 % 2.73 % Volatility 96.57 % 80.83 % Expected lives (years) 6.20 6.20 Expected dividend yield — % — % There were no stock options granted during the three months ended September 30, 2019 and 2018. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2019 and 2018 was $54.00 and $186.50 , respectively. The Company’s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company’s options of ten years with the average vesting term of four years for an average of approximately six years . The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero , because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur. As of September 30, 2019 , there was $1.1 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company’s operating expenses over a weighted-average period of 2.53 years. The following table summarizes stock option activity of the Company for the nine months ended September 30, 2019 : Total Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (In Thousands) Outstanding at December 31, 2018 7,650 $ 261.09 9.01 $ — Granted 18,800 69.00 $ — Canceled (3,264 ) 191.05 $ — Outstanding at September 30, 2019 23,186 $ 115.19 9.22 $ — Options exercisable at September 30, 2019 2,486 $ 261.22 8.51 $ — The aggregate intrinsic values of outstanding and exercisable stock options at September 30, 2019 were calculated based on the closing price of the Company’s common stock as reported on the Nasdaq Capital Market on September 30, 2019 of $6.00 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying stock options. RSUs with Time-Based and Performance-Based Conditions The Company granted Restricted Stock Units ("RSUs") subject to both time-based and performance-based vesting conditions to certain of its employees and non-employees pursuant to the Company's 2016 Incentive Plan. These RSUs vest based on both (i) continued service either over a three -year measurement period or at the end of the required service period and (ii) the achievement of a liquidity event. The initial vesting date for these RSUs was February 27, 2018. The liquidity event, as defined in the relevant RSU grant agreements, will be satisfied upon the earlier of either: (a) change of control or (b) a qualified public offering. During the three months ended September 30, 2019 , approximately 230 shares of common stock were issued in connection upon the vesting of RSUs. As of September 30, 2019, there were no RSUs outstanding under any of the Company's incentive plans.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated all events or transactions that occurred after September 30, 2019 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the condensed consolidated financial statements, including below, the Company did not have any material subsequent events. On October 29, 2019, the Company entered into a Distribution Agreement with Maxim Group LLC as described in Notes 3 and 7. On November 6, 2019, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1 for 50 reverse stock split of the Company's outstanding shares of common stock which became effective on November 7, 2019 as described in Note 3.

Basis Of Presentation and Sig_2

Basis Of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, Sellas Life Sciences Group UK Ltd., and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.
Preferred Stock	Preferred Stock The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Recent Accounting Pronouncements Adopted	Recent Accounting Pronouncements Adopted In July 2019, the FASB issued Accounting Standards Update ("ASU") No. 2019-07, Codification Updates to SEC Sections - Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update). ASU No. 2019-07 clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. ASU No. 2019-07 became effective upon issuance and the adoption of ASU No. 2019-07, which is applied prospectively, did not have an impact on the Company’s consolidated financial statements and disclosures. On January 1, 2019, the Company adopted ASU No. 2016-02, Leases ( Topic 842 ), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use ("ROU") assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. The new guidance retains a distinction between finance leases and operating leases, while requiring companies to recognize both types of leases on their balance sheet. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the criteria for distinguishing between capital leases and operating leases in legacy U.S. GAAP - ASC 840. The Company adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company evaluated the potential cumulative effect of applying the new guidance and determined that such an adjustment would be immaterial. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the Company's historical accounting under Topic 840. Under Topic 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company's incremental borrowing rate is a hypothetical rate based on the Company's understanding of what the Company's credit rating would be. The Company's lease terms may include options to extend or terminate the lease and the related payments are only included in the lease liability when it is reasonably certain that the Company will exercise such options. In connection with the adoption, the Company did not separate lease and associated non-lease components for the transitioned leases, but instead are accounting for them together as a single component. The adoption did not change the classification of lease-related expenses in the condensed consolidated statements of operations, and the Company does not expect changes to the pattern of expense recognition. As a result, the adoption does not impact the Company's beginning retained earnings, or the Company's prior year condensed consolidated statements of operations and will not materially affect the condensed consolidated statements of cash flows. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity Topic (480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instrument with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception , which modifies the classification of some financial instruments. A down round feature no longer precludes equity classification, therefore a freestanding equity feature would no longer be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities present earnings per share in accordance with Topic 260, and to recognize the effect of the down round feature when triggered. Convertible instruments are now subject to specialized contingent beneficial conversion features. The Company adopted ASU No. 2017-11 on January 1, 2019 and determined it did not have a material impact to its condensed consolidated financial statements. The Company determined its liability classified warrants contained cash settlement features that would continue to preclude equity classification subsequent to its adoption of ASU No. 2017-11. Recent Accounting Pronouncements Pending Adoption In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Accounting , which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. ASU No. 2018-07 generally requires an entity to use a modified retrospective transition approach, with a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1) liability-classified nonemployee awards that have not been settled as of the adoption date and (2) equity-classified nonemployee awards for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements. In August 2018, FASB issued No. ASU 2018-13, Fair Value Measurement (Topic 820) Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement . ASU No. 2018-13 modifies, adds and removes certain specific disclosure requirements on fair value measurements in Topic 820 . The amendments in ASU 2018-13 are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU No. 2018-13 and to delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the potential impact of the adoption of the new standard on the consolidated financial statements.

Basis Of Presentation and Sig_3

Basis Of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Cash and Cash Equivalents	The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands): September 30, 2019 December 31, 2018 Cash and cash equivalents $ 9,119 $ 5,337 Restricted cash and cash equivalents 115 114 Total cash, cash equivalents, restricted cash, and restricted cash equivalents $ 9,234 $ 5,451
Restricted Cash and Cash Equivalents	The following table provides a reconciliation of the components of cash, cash equivalents, restricted cash, and restricted cash equivalents reported in the Company's condensed consolidated balance sheets to the total of the amount presented in the condensed consolidated statements of cash flows (in thousands): September 30, 2019 December 31, 2018 Cash and cash equivalents $ 9,119 $ 5,337 Restricted cash and cash equivalents 115 114 Total cash, cash equivalents, restricted cash, and restricted cash equivalents $ 9,234 $ 5,451

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value	The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands): Description September 30, 2019 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 9,055 $ 9,055 $ — $ — Total assets measured and recorded at fair value $ 9,055 $ 9,055 $ — $ — Liabilities: Warrant liability $ 80 $ — $ — $ 80 Contingent consideration 4,836 — — 4,836 Total liabilities measured and recorded at fair value $ 4,916 $ — $ — $ 4,916 Description December 31, 2018 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 5,195 $ 5,195 $ — $ — Total assets measured and recorded at fair value $ 5,195 $ 5,195 $ — $ — Liabilities: Warrant liability $ 1,013 $ — $ — $ 1,013 Contingent consideration 4,326 — — 4,326 Total liabilities measured and recorded at fair value $ 5,339 $ — $ — $ 5,339
Reconciliation of Level 3 Liabilities	A reconciliation of the change in the fair value of the contingent consideration liability for the nine months ended September 30, 2019 is as follows (in thousands): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Contingent consideration, December 31, 2018 $ 4,326 Change in the estimated fair value of the contingent consideration 510 Contingent consideration, September 30, 2019 $ 4,836

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current liabilities consist of the following (in thousands): September 30, 2019 December 31, 2018 Insurance $ 479 $ 154 Clinical development 347 48 Professional services 107 56 Other 44 129 Prepaid expenses and other current assets $ 977 $ 387
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): September 30, 2019 December 31, 2018 Compensation and related benefits $ 735 $ 675 Clinical trial costs 441 858 Professional fees 328 540 Rebates and returns of former commercial products — 138 Other — 8 Accrued expenses and other current liabilities $ 1,504 $ 2,219

Legal Proceedings, Commitment_2

Legal Proceedings, Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments - Topic 842	Future minimum rental payments under the Company's non-cancelable operating lease are as follows as of September 30, 2019 (in thousands): September 30, 2019 Year ending December 31, 2019 (remaining three months) $ 96 Year ending December 31, 2020 224 Total minimum lease payments 320 Less: imputed interest (14 ) Operating lease liabilities $ 306
Future Minimum Lease Payments - Topic 840	Future minimum rental payments under the Company's non-cancelable operating lease as of December 31, 2018 were as follows (in thousands): December 31, 2018 2019 $ 377 2020 224 Total minimum lease payments $ 601

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Common Stock Reserved for Future Issuance	As of September 30, 2019, the Company has shares of common stock reserved for future issuance for as follows (in thousands): September 30, 2019 Warrants outstanding 302 Stock options outstanding 23 Options reserved for future issuance under the Company’s 2019 Equity Incentive Plan 201 Shares reserved for future issuance under the Employee Stock Purchase Plan 5 Total common stock reserved for future issuance 531

Warrants to Acquire Shares of_2

Warrants to Acquire Shares of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2019
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrant Activity Table	The following is a summary of the Company's warrants to acquire shares of common stock activity for the nine months ended September 30, 2019 (in thousands): Warrant Issuance Outstanding, December 31, 2018 Granted Exercised Canceled/Expired Outstanding, September 30, 2019 Expiration June 2019 Offering — 2,000 (1,998 ) — 2 June 2024 Pre-funded June 2019 Offering — 1,473 (1,473 ) — — June 2024 March 2019 Exercise Agreement — 63 — — 63 March 2024 July 2018 Offering 305 — (97 ) — 208 July 2023 Pre-funded July 2018 Offering 13 — (13 ) — — July 2023 Series A Convertible Preferred 28 — (9 ) — 19 September 2023 2017 Equilibria 6 — — — 6 December 2022 Galena February 2017 1 — — — 1 February 2022 Galena Other 3 — — — 3 January 2022 356 3,536 (3,590 ) — 302
Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model	The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: As of September 30, 2019 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Series A Convertible Preferred 19 $ 7.50 4.01 105.47 % 1.56 % Galena February 2017 1 $ 1,650.00 2.38 107.21 % 1.56 % Galena Other 3 $ 41,494.00 1.68 107.21 % 1.56 % As of December 31, 2018 Warrant Issuance Outstanding (in thousands) Strike price (per share) Expected term (years) Volatility % Risk-free rate % Series A Convertible Preferred 28 $ 7.50 4.76 88.80 % 2.50 % Galena February 2017 1 $ 1,650.00 3.12 94.12 % 2.46 % Galena Other 3 $ 41,494.00 2.43 94.73 % 2.46 %
Changes in Fair Value of Warrant Liability	The changes in fair value of the warrant liability for the nine months ended September 30, 2019 were as follows (in thousands): Warrant Issuance Warrant liability, December 31, 2018 Fair value of warrants granted Fair value of warrants exercised Adjustment to exercise price of warrants Change in fair value of warrants Warrant liability, September 30, 2019 Series A Convertible Preferred $ 1,010 $ — $ (68 ) $ 243 $ (1,108 ) $ 77 Galena February 2017 3 — — — — 3 $ 1,013 $ — $ (68 ) $ 243 $ (1,108 ) $ 80

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Allocated Stock-based Compensation Expense	The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of operations for the three and nine months ended September 30, 2019 and 2018 , respectively (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development $ (1 ) $ 21 $ (4 ) $ 55 General and administrative 116 115 430 229 Total stock-based compensation $ 115 $ 136 $ 426 $ 284
Assumptions for Option Grants Issued	The Company uses the Black-Scholes option-pricing model and the following assumptions were used to determine the fair value of all its stock options granted during the nine months ended September 30, 2019 and 2018: Nine Months Ended September 30, 2019 2018 Risk free interest rate 2.49 % 2.73 % Volatility 96.57 % 80.83 % Expected lives (years) 6.20 6.20 Expected dividend yield — % — %
Stock Option Activity	The following table summarizes stock option activity of the Company for the nine months ended September 30, 2019 : Total Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (In Thousands) Outstanding at December 31, 2018 7,650 $ 261.09 9.01 $ — Granted 18,800 69.00 $ — Canceled (3,264 ) 191.05 $ — Outstanding at September 30, 2019 23,186 $ 115.19 9.22 $ — Options exercisable at September 30, 2019 2,486 $ 261.22 8.51 $ —

Liquidity (Details)

Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 29, 2019	Jun. 18, 2019	Nov. 14, 2019	Sep. 30, 2019	Mar. 06, 2019	Dec. 31, 2018	Jul. 16, 2018	Dec. 29, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants issued (in shares)		2,000,000
Sale of stock, price per share (in dollars per share)		$ 25
Number of warrants exercised (in shares)				3,590,000
Warrants outstanding (in shares)				302,000		356,000
Exercise price of pre-funded warrants (in dollars per share)		$ 0.005
Net proceeds of common stock		$ 13,400
Warrant exercise price (in dollars per share)								$ 371
Number of warrants issued (in shares)				3,536,000
Cash and cash equivalents				$ 9,119		$ 5,337
Restricted cash and cash equivalents				115		114
Accumulated deficit				93,728		$ 81,855
Accounts payable and accrued liabilities				$ 5,600
Distribution Agreement | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of stock (in shares)			322,719
Net proceeds of common stock			$ 1,900
Sale of shares, common stock gross proceeds	$ 5,000
Percentage gross proceeds from the sale of share	3.00%
June 2019 Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants exercised (in shares)				1,997,740
Warrants outstanding (in shares)				2,260
2018 Warrants
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants exercised (in shares)				63,000
Number of warrants to be exercised (in shares)					76,000
Warrant exercise price (in dollars per share)					$ 55		$ 105
Gross proceeds from warrant exercises				$ 3,500
Warrant Exercise Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants exercised (in shares)				0
Warrants outstanding (in shares)				63,000		0
Warrant exercise price (in dollars per share)					$ 70
Number of warrants issued (in shares)				63,000
Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of stock (in shares)		527,344
Sale of stock, price per share (in dollars per share)		$ 7.5					$ 7.5
Warrant
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares of stock (in shares)		1,472,656
Sale of stock, price per share (in dollars per share)		$ 7.495

Basis Of Presentation and Sig_4

Basis Of Presentation and Significant Accounting Policies (Details) $ in Thousands	Nov. 07, 2019shares	Nov. 08, 2019shares	Sep. 30, 2019USD ($)shares	Dec. 31, 2018USD ($)shares	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Subsequent Event [Line Items]
Common stock, shares outstanding (in shares) | shares			4,549,208	440,529
Cash and cash equivalents			$ 9,119	$ 5,337
Restricted cash and cash equivalents			115	114
Total cash, cash equivalents, restricted cash, and restricted cash equivalents			$ 9,234	$ 5,451	$ 10,082	$ 12,750
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split company's outstanding shares of common stock	0.02
Common stock, shares outstanding (in shares) | shares	227,800,147	4,549,208

Fair Value Measurements - Conti

Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Liabilities:
Warrant liability	$ 80	$ 1,013
Fair Value, Measurements, Recurring
Assets:
Cash equivalents	9,055	5,195
Total assets measured and recorded at fair value	9,055	5,195
Liabilities:
Warrant liability	80	1,013
Contingent consideration	4,836	4,326
Total liabilities measured and recorded at fair value	4,916	5,339
Fair Value, Measurements, Recurring | Quoted Prices In Active Markets (Level 1)
Assets:
Cash equivalents	9,055	5,195
Total assets measured and recorded at fair value	9,055	5,195
Liabilities:
Warrant liability	0	0
Contingent consideration	0	0
Total liabilities measured and recorded at fair value	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Assets:
Cash equivalents	0	0
Total assets measured and recorded at fair value	0	0
Liabilities:
Warrant liability	0	0
Contingent consideration	0	0
Total liabilities measured and recorded at fair value	0	0
Fair Value, Measurements, Recurring | Unobservable Inputs (Level 3)
Assets:
Cash equivalents	0	0
Total assets measured and recorded at fair value	0	0
Liabilities:
Warrant liability	80	1,013
Contingent consideration	4,836	4,326
Total liabilities measured and recorded at fair value	$ 4,916	$ 5,339

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Apthera, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration payable, maximum amount	$ 32,000
Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration, beginning balance	4,326
Change in the estimated fair value of the contingent consideration	510
Contingent consideration, ending balance	$ 4,836

Balance Sheet Accounts - Prepai

Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Insurance	$ 479	$ 154
Clinical development	347	48
Professional services	107	56
Other	44	129
Prepaid expenses and other current assets	$ 977	$ 387

Balance Sheet Accounts - Accrue

Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation and related benefits	$ 735	$ 675
Clinical trial costs	441	858
Professional fees	328	540
Rebates and returns of former commercial products	0	138
Other	0	8
Accrued expenses and other current liabilities	$ 1,504	$ 2,219

Legal Proceedings, Commitment_3

Legal Proceedings, Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands	Nov. 13, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease liability, current		$ 306		$ 306
Operating lease liability, non-current		0		0
Operating lease right-of-use asset		$ 306		$ 306
Operating lease, discount rate		13.00%		13.00%
Operating lease, remaining term				1 year
Rent expense, Topic 842		$ 100		$ 300
Rent expense, Topic 840			$ 100		$ 300
Operating lease amortization		$ 100		$ 200
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease liability, current						$ 400
Operating lease liability, non-current						200
Operating lease right-of-use asset						$ 600
Class Action Complaints | Subsequent Event
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Period to file amended complaint	30 days

Legal Proceedings, Commitment_4

Legal Proceedings, Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details) $ in Thousands	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Year ending December 31, 2019 (remaining three months)	$ 96
Year ending December 31, 2020	224
Total minimum lease payments	320
Less: imputed interest	(14)
Operating lease liabilities	$ 306

Legal Proceedings, Commitment_5

Legal Proceedings, Commitments and Contingencies - Maturities of Lease Liabilities - 840 (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 377
2020	224
Total minimum lease payments	$ 601

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Oct. 29, 2019	Jun. 18, 2019	Nov. 14, 2019	Sep. 30, 2019	Dec. 31, 2018	Jul. 16, 2018
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)				5,000,000	5,000,000
Preferred stock, par value (in dollars per share)				$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)				350,000,000	350,000,000
Common stock, par value (in dollars per share)				$ 0.0001	$ 0.0001
Net proceeds of common stock		$ 13.4
Warrants issued (in shares)		2,000,000
Sale of stock, price per share (in dollars per share)		$ 25
Warrant exercise price (in dollars per share)		$ 0.005
Common Stock
Class of Stock [Line Items]
Number of shares of stock (in shares)		527,344
Sale of stock, price per share (in dollars per share)		$ 7.5				$ 7.5
Common Stock Warrant
Class of Stock [Line Items]
Number of shares of stock (in shares)		1,472,656
Sale of stock, price per share (in dollars per share)		$ 7.495
Distribution Agreement | Subsequent Event
Class of Stock [Line Items]
Sale of shares, common stock gross proceeds	$ 5
Percentage gross proceeds from the sale of share	3.00%
Number of shares of stock (in shares)			322,719
Net proceeds of common stock			$ 1.9

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details) - shares	Sep. 30, 2019	Dec. 31, 2018
Equity [Abstract]
Warrants outstanding	302,000	356,000
Stock options outstanding	23,186	7,650
Options reserved for future issuance under the Company’s 2019 Equity Incentive Plan	201,000
Shares reserved for future issuance under the Employee Stock Purchase Plan	5,000
Total common stock reserved for future issuance	531,000

Warrants to Acquire Shares of_3

Warrants to Acquire Shares of Common Stock - Warrants Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 18, 2019	Mar. 06, 2019	Jul. 16, 2018	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Nov. 08, 2019	Jul. 08, 2019	Jul. 07, 2019	May 31, 2018	Dec. 29, 2017
Class of Warrant or Right [Line Items]
Common stock to be called by warrants (in shares)											6,323
Warrant exercise price (in dollars per share)											$ 371
Number of warrants exercised (in shares)					3,590,000
Number of warrants issued (in shares)					3,536,000
Increase to warranty liability fair value					$ 243	$ 491
Sale of stock, price per share (in dollars per share)	$ 25
2018 Warrants
Class of Warrant or Right [Line Items]
Common stock to be called by warrants (in shares)			230,400
Warrant exercise price (in dollars per share)		$ 55	$ 105
Number of warrants to be exercised (in shares)		76,000
Number of warrants exercised (in shares)					63,000
Gross proceeds from warrant exercises					$ 3,500
Decrease (increase) in warrant fair value			$ (800)		$ (300)
Warrant Exercise Agreement
Class of Warrant or Right [Line Items]
Warrant exercise price (in dollars per share)		$ 70
New warrants available for issuance (in shares)		76,000
Warrant expiration period		5 years
Number of warrants exercised (in shares)					0
Number of warrants issued (in shares)					63,000
Series A Convertible Preferred
Class of Warrant or Right [Line Items]
Warrant exercise price (in dollars per share)	$ 7.5	$ 55	$ 105							$ 105
Number of warrants exercised (in shares)					9,000
Number of warrants issued (in shares)					0
Increase to warranty liability fair value	$ 100	$ 300
Series A Convertible Preferred | Subsequent Event
Class of Warrant or Right [Line Items]
Warrant exercise price (in dollars per share)							$ 7.5
Warrant Investor Agreements
Class of Warrant or Right [Line Items]
Warrant exercise price (in dollars per share)								$ 0	$ 25
Decrease (increase) in warrant fair value				$ 7,300	$ 7,300
Common Stock
Class of Warrant or Right [Line Items]
Sale of stock, price per share (in dollars per share)	$ 7.5		$ 7.5

Warrants to Acquire Shares of_4

Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2019shares
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	356
Granted	3,536
Exercised	(3,590)
Canceled/Expired	0
Outstanding, end of period	302
June 2019 Offering
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	0
Granted	2,000
Exercised	(1,998)
Canceled/Expired	0
Outstanding, end of period	2
Pre-funded June 2019 Offering
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	0
Granted	1,473
Exercised	(1,473)
Canceled/Expired	0
Outstanding, end of period	0
March 2019 Exercise Agreement
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	0
Granted	63
Exercised	0
Canceled/Expired	0
Outstanding, end of period	63
July 2018 Offering
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	305
Granted	0
Exercised	(97)
Canceled/Expired	0
Outstanding, end of period	208
Pre-funded July 2018 Offering
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	13
Granted	0
Exercised	(13)
Canceled/Expired	0
Outstanding, end of period	0
Series A Convertible Preferred
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	28
Granted	0
Exercised	(9)
Canceled/Expired	0
Outstanding, end of period	19
2017 Equilibria
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	6
Granted	0
Exercised	0
Canceled/Expired	0
Outstanding, end of period	6
Galena February 2017
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	1
Granted	0
Exercised	0
Canceled/Expired	0
Outstanding, end of period	1
Galena Other
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding, beginning of period	3
Granted	0
Exercised	0
Canceled/Expired	0
Outstanding, end of period	3

Warrants to Acquire Shares of_5

Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	302	356
Measurement Input, Risk Free Interest Rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input	0
Measurement Input, Expected Dividend Rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input	0
Series A Convertible Preferred
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	19	28
Strike price (in dollars per share)	$ 7.5	$ 7.5
Expected term	4 years 4 days	4 years 9 months 4 days
Volatility %	105.47%	88.80%
Risk-free rate %	1.56%	2.50%
Galena February 2017
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	1	1
Strike price (in dollars per share)	$ 1,650	$ 1,650
Expected term	2 years 4 months 17 days	3 years 1 month 13 days
Volatility %	107.21%	94.12%
Risk-free rate %	1.56%	2.46%
Galena Other
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	3	3
Strike price (in dollars per share)	$ 41,494	$ 41,494
Expected term	1 year 8 months 4 days	2 years 5 months 5 days
Volatility %	107.21%	94.73%
Risk-free rate %	1.56%	2.46%

Warrants to Acquire Shares of_6

Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, beginning balance	$ 1,013
Fair value of warrants granted	0
Fair value of warrants exercised	(68)
Adjustment to exercise price of warrants	243
Change in fair value of warrants	(1,108)
Warrant liability, ending balance	80
Series A Convertible Preferred
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, beginning balance	1,010
Fair value of warrants granted	0
Fair value of warrants exercised	(68)
Adjustment to exercise price of warrants	243
Change in fair value of warrants	(1,108)
Warrant liability, ending balance	77
Galena February 2017
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, beginning balance	3
Fair value of warrants granted	0
Fair value of warrants exercised	0
Adjustment to exercise price of warrants	0
Change in fair value of warrants	0
Warrant liability, ending balance	$ 3

Warrants to Acquire Shares of_7

Warrants to Acquire Shares of Common Stock - Warrants Classified as Equity (Details)	Dec. 29, 2017$ / sharesshares
Warrants and Rights Note Disclosure [Abstract]
Warrants issued (in shares) | shares	6,323
Warrant exercise price (in dollars per share) | $ / shares	$ 371
Warrant term	5 years

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 10, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 29, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance (in shares)		531,000		531,000
Granted (in shares)		0	0	18,800
Weighted average exercise price, granted (in dollars per share)				$ 54	$ 186.50
Averages contractual term				10 years
Expected dividend yield				0.00%	0.00%
Unrecognized compensation cost				$ 1.1
Operating expenses weighted average period				2 years 6 months 10 days
Closing price of the Company's common stock (in dollars per share)		$ 6		$ 6
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options, vesting period				3 years
Equity instruments other than options, outstanding, number (in shares)		230		230
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average vesting term				6 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average vesting term				4 years
2017 Equity Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance (in shares)		1,018		1,018
2017 Equity Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock authorized for issuance (in shares)						24,204
2019 Incentive plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock authorized for issuance (in shares)	200,000
Shares of common stock reserved for issuance (in shares)		201,018		201,018
Options expire from date of grant	4 years
Percentage increase in number of shares available for future issuance under stock based awards	5.00%

Stock-Based Compensation - Allo

Stock-Based Compensation - Allocated Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 115	$ 136	$ 426	$ 284
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	(1)	21	(4)	55
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 116	$ 115	$ 430	$ 229

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions for Option Grants Issued (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
Risk free interest rate	2.49%	2.73%
Volatility	96.57%	80.83%
Expected lives (years)	6 years 2 months 12 days	6 years 2 months 12 days
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2019
Total Number of Shares
Options outstanding, beginning balance (in shares)	23,186		23,186	7,650	23,186
Granted (in shares)	0	0	18,800
Canceled (in shares)			(3,264)
Options outstanding, ending balance (in shares)	23,186		23,186	7,650
Exercisable (in shares)					2,486
Weighted Average Exercise Price
Beginning balance (in dollars per share)			$ 261.09
Granted (in dollars per share)			69
Canceled (in dollars per share)			191.05
Ending balance (in dollars per share)	$ 115.19		$ 115.19	$ 261.09
Exercisable (in dollars per share)					$ 261.22
Weighted average remaining contractual term, outstanding			9 years 2 months 19 days	9 years 4 days
Weighted average remaining contractual term, options exercisable			8 years 6 months 3 days
Aggregate Intrinsic Value
Beginning balance			$ 0
Granted			0
Canceled			0
Ending balance	$ 0		$ 0	$ 0
Exercisable					$ 0

Subsequent Events (Details)

Subsequent Events (Details)	Nov. 07, 2019
Subsequent Event
Subsequent Event [Line Items]
Reverse stock split company's outstanding shares of common stock	0.02